These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8571733)

  • 21. Signaling through the lymphotoxin-beta receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF-alpha.
    Marshall WL; Brinkman BM; Ambrose CM; Pesavento PA; Uglialoro AM; Teng E; Finberg RW; Browning JL; Goldfeld AE
    J Immunol; 1999 May; 162(10):6016-23. PubMed ID: 10229841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor family ligand-receptor binding.
    Zhang G
    Curr Opin Struct Biol; 2004 Apr; 14(2):154-60. PubMed ID: 15093829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.
    Tosato G; Teruya-Feldstein J; Setsuda J; Pike SE; Jones KD; Jaffe ES
    Springer Semin Immunopathol; 1998; 20(3-4):405-23. PubMed ID: 9870254
    [No Abstract]   [Full Text] [Related]  

  • 24. Modulation of death receptor signalling.
    Schneider P; Tschopp J
    Symp Soc Exp Biol; 2000; 52():31-42. PubMed ID: 12090018
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
    Younes A; Kadin ME
    J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of an adenovirally encoded lymphotoxin-beta inhibitor prevents clearance of Listeria monocytogenes in mice.
    Trüeb R; Brown G; Van Huffel C; Poltorak A; Valdez-Silva M; Beutler B
    J Inflamm; 1995; 45(4):239-47. PubMed ID: 8867668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
    Robak T; Gladalska A; Stepień H
    Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced sensitivity of tumor necrosis factor/lymphotoxin-alpha-deficient mice to Cryptococcus neoformans infection despite increased levels of nitrite/nitrate, interferon-gamma, and interleukin-12.
    Rayhane N; Lortholary O; Fitting C; Callebert J; Huerre M; Dromer F; Cavaillon JM
    J Infect Dis; 1999 Nov; 180(5):1637-47. PubMed ID: 10515827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells.
    Kashii Y; Giorda R; Herberman RB; Whiteside TL; Vujanovic NL
    J Immunol; 1999 Nov; 163(10):5358-66. PubMed ID: 10553060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune lymphoproliferative syndromes (ALPS): models for the study of peripheral tolerance.
    Fischer A; Rieux-Laucat F; Le Deist F
    Rev Immunogenet; 2000; 2(1):52-60. PubMed ID: 11324693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.
    Hochman PS; Majeau GR; Mackay F; Browning JL
    J Inflamm; 1995-1996; 46(4):220-34. PubMed ID: 8878796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.
    Eissner G; Kolch W; Scheurich P
    Cytokine Growth Factor Rev; 2004 Oct; 15(5):353-66. PubMed ID: 15450251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphotoxin-beta and TNF regulation in T cell subsets: differential effects of PGE2.
    Ferreri NR; Millet I; Askari B; Magnani P; Ruddle NH
    Cytokine; 1997 Mar; 9(3):157-65. PubMed ID: 9126704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factors: developments during the last decade.
    Aggarwal BB; Natarajan K
    Eur Cytokine Netw; 1996; 7(2):93-124. PubMed ID: 8688493
    [No Abstract]   [Full Text] [Related]  

  • 36. Recognition and destruction of tumor cells by natural killer cells.
    Riccardi C; Migliorati G
    Ann Ist Super Sanita; 1988; 24(1):83-8. PubMed ID: 3289446
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytotoxins (tumour necrosis factor, lymphotoxin and others): molecular and functional characteristics and interactions with interferons.
    Wallach D
    Interferon; 1986; 7():89-124. PubMed ID: 2434436
    [No Abstract]   [Full Text] [Related]  

  • 38. [Tumor markers in lymphoproliferative disorders].
    Ohtsu T
    Nihon Rinsho; 1996 Jun; 54(6):1621-5. PubMed ID: 8691619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tumor necrosis factor. From theory to practice].
    Boudes P; Guillevin L
    Ann Med Interne (Paris); 1989; 140(8):715-20. PubMed ID: 2698074
    [No Abstract]   [Full Text] [Related]  

  • 40. The biochemistry and pharmacology of TNF alpha and beta, 21 April 1995, New York.
    Carty TJ; Gilman SC
    Inflamm Res; 1995 Nov; 44(11):455-7. PubMed ID: 8597876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.